M&As this week: RxCelerate, HealthCare Global Enterprises, REPROCELL

4th May 2018 (Last Updated August 12th, 2019 10:39)

RxCelerate Ltd has acquired Total Scientific Ltd, a contract research organisation.

RxCelerate Ltd has acquired Total Scientific Ltd, a contract research organisation.

The Total Scientific brand will be withdrawn and the company’s services will be provided only through RxCelerate, upon completion of the acquisition.

Based in the UK, RxCelerate is an outsourced drug development company.

The acquisition will improve RxCelerate’s position in the outsourced drug development market.

HealthCare Global Enterprises Ltd has agreed to purchase a 12% share in International Stemcell Services Ltd (ISSL) for Rs5.61m ($84,000).

HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal.

"HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal."

Based in India, HealthCare Global Enterprises is engaged in the provision of cancer care services.

REPROCELL Incorporated has acquired BioServe Biotechnologies (India) Private Limited from Cancer Genetics Inc for $1.9m.

REPROCELL has made an upfront payment of $1.6m in cash to Cancer Genetics as part of the transaction.

The company will pay the remaining amount based on BioServe’s revenue for a four-month period being similar to that of the same period in 2017.

Based in India, REPROCELL Incorporated is a biomedical research company, while BioServe is a DNA extraction, synthesis, sequencing and related services provider.

Raymond James & Associates Inc was appointed as the financial adviser for the transaction by Cancer Genetics.